

Description of CiNA Public Use Dataset

The NAACCR CiNA-Public Dataset is a new CiNA product that was first available for 1995-2013 data. The goal behind producing the CiNA Public Use Dataset is to provide faster, streamlined access to the CiNA data in order to increase CiNA data use and, ultimately, reduce the burden of cancer. The data will be available annually after publication of the CiNA monographs; generally in the summer.

The CiNA Public Use Dataset is a publically accessible, non-confidential data set with a limited number of variables, available in the SEER*Stat program. Access requires only a signed Data Use Agreement for access. There are other CiNA databases with more extensive variable set that require a proposal review, NAACCR IRB approval, and a “yes” consent by each participating registry. The CiNA Public Use the variable list is included at the end of this document. Many variables are recoded from the reported data for ease of use and standardization of analysis. There are no treatment variables available in the CiNA Public Use Dataset.

The dataset is comprised of two datasets. One allows a user to generate counts, rates and trends within the SEER*Stat system. This dataset includes age in the 19 age group categories. The second dataset allows the user to export the data as a case-listing to allow regression and other analysis in standard, statistical programs. This second dataset includes both age and site as categorical variables for US combined and Canada combined. A researcher will be able to access both data sets in the same SEER*Stat session but will only be able to export data from registries that have provided consent. SEER*Stat provides automatic cell suppression of <6 and scrambles the Patient IDs. *At this time, the database allowing exporting is still under development.*

Additional details about the CiNA Public Use Dataset are provided in this Appendix. If you have questions about the NAACCR CiNA Public Dataset, please contact Recinda Sherman, Manager of Research and Data Use at rsherman@naaccr.org or 217-698-0800 x6.

Data Use Agreement for Researcher Access to the Public Use Data Set NAACCR CiNA-Public Dataset 1995-2015

These data are provided for the sole purpose of statistical reporting and analysis only. By using these data, you signify your agreement to comply with the following:

1. There will be no attempt to learn the identity of any person included in these data. If the identity of any person is discovered inadvertently, no disclosure or other use of the identity will be made, **and I will notify NAACCR.**
Initials required: _____
2. The identification or contact of individuals is prohibited. I will not discuss in any manner, with any unauthorized person, information that would lead to identification of individuals described in the Data furnished by NAACCR.
Initials required: _____
3. I will not attempt either to link—**or permit others to link**—the data with individually identified records in another database.
Initials required: _____
4. I will not either release—**or permit others to release**—the data—in full or in part—to any person. I will not share my password for data access with any other individuals. All members of a research team who have access to the data must sign this data-use agreement.
Initials required: _____
5. I will not use—or permit others to use—the data in any way other than for statistical reporting and analysis for public health research purposes. I must notify NAACCR if I discover that there has been any other use of the data.
Initials required: _____
6. I agree that all data provided shall remain the sole property of NAACCR and may not be copied or reproduced in any form or manner without NAACCR's prior written consent.
Initials required: _____
7. I will cite the source of information in all publications. The appropriate citation is associated with the data file used.
Initials required: _____
8. Uses of these data do not constitute an endorsement of the user's opinion or conclusions by NAACCR, or any central registry in US or Canada, and none should be inferred.
Initials required: _____
9. I understand that calculating rates or other statistics based on small numbers can raise statistical issues concerning accuracy and usefulness. I will use appropriate caution when presenting and interpreting results based on less than 20 cases.
Initials required: _____
10. I agree that any and all reports or analyses of the Data shall contain only aggregate data and no report of the Data containing statistical cells with less than six (6) subjects shall be released.
Initials required: _____

My signature indicates that I agree to comply with the above stated provisions.

First Name:
Organization:
Phone:
Date:

Last Name:
Email:

Signature:

Questions or issues, please contact Recinda Sherman, rsherman@naaccr.org.

Citation

Please reference to the source of these data in any published document as indicated in SEER*Stat session.

For example:

NAACCR Incidence - CiNA Public File, 1995-2015 (which includes data from CDC's National Program of Cancer Registries (NPCR), CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results (SEER) Registries), North American Association of Central Cancer Registries.

Technical Documentation

The NAACCR CiNA-Public Dataset is distributed through SEER*Stat and contains individual records of cancer incidence among US and Canada residents diagnosed from 1995 – 2015. Confidentiality is maintained by aggregating data within individual records into categories, the number of which depends on whether analysis is run on individual states/registries or nation/North America.

The purpose of releasing cancer surveillance data is to inform public health decision making. Cancer rates are often needed for subgroups or for small populations in order to understand the burden of cancer in these groups or areas. But working with small numbers has two problems 1) working with small numbers, particularly linking with external data, has the potential for confidentiality breaches; and 2) small numbers raise statistical issues regarding the accuracy and, ultimately, the usefulness of the data.

- To preserve confidentiality of the data, data will be automatically suppressed for counts less than 6 based on potentially linkable variables (registry, sex, age, race, race/ethnicity, year of diagnosis and site). Please note, counts less than six may be released for other variables including behavior, stage or histology. However, these variables are not considered identifying variables.
- For issues of statistical stability, we advise caution in interpreting rates and other results based on fewer than 25 cases.

Software

SEER*Stat statistical software is a standard tool for analysis of cancer-related data. SEER*Stat is distributed with the CiNA Public Dataset. Additional information on SEER*Stat is available on the NCI, SEER site: <http://seer.cancer.gov/seerstat/>. Tutorials are available here: <http://seer.cancer.gov/seerstat/tutorials/>. Delay factors, survival statistics, and prevalence are not currently available for the CiNA Public Dataset.

Representation

To be included in the CiNA Public dataset, a central registry from the US or Canada must meet specific data quality standards. All Gold and Silver NAACCR-certified central registries are eligible for inclusion in the CiNA Public dataset. Each central registry must also consent to the use of their data in the CiNA Public dataset. A current list of certified

registries is available here: <https://www.naaccr.org/certified-registries/>. Registries may have not been certified in prior years, but if their data quality improves over time, their data is included in CiNA. However, not all states meet the data quality criteria for each year and will have zero counts for those years. Current CiNA Public Use dataset contains 46 states plus DC and PR for the US, and 12 Canadian provinces covering 93% of the US and 64% of the Canada population.

Data Collection

Cancer registry data is collected in an on-going, systematic, and standardized process. In Canada, the cancer registry collection program is overseen by the Canadian Council of Cancer Registries. In the US, there are two cancer registry collection programs—the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER Program) and the Center for Disease Control’s National Program of Cancer Registries (NPCR). Data for all three programs is collected in a coordinated process from hospitals and other medical facilities, including inpatient, outpatient, and standalone facilities. The data is collected or overseen by certified tumor registrars (CTRs) who are highly trained medical professionals to ensure complete and high quality data collection. The International Classification of Disease-Oncology (ICD-O) coding system is used to code topography (primary site) and morphology (histologic characteristics) of the collected cancers. Additional coding information is available in the NAACCR Data Standards & Data Dictionary (Volume II) available here: <https://www.naaccr.org/data-standards-data-dictionary/>.

Please note, the variables available in the CiNA Public Dataset are a subset of the full variable list collected. Many variables in the CiNA Public Dataset are aggregated and recoded for analysis.

Cancer Coding Changes Over Time

Several definitional changes occurred in some histology and behavior codes in ICD-O-3 that affected the inclusion and exclusion of reportable cancers diagnosed beginning in 2001. The changes predominately affected leukemias, lymphomas, and cancer of the ovary. One category of change between ICD-O-2 and ICD-O-3 is the manner in which leukemias and lymphomas are classified and coded. Although conversion of histology codes from ICD-O-2 to ICD-O-3 for cases diagnosed prior to 2001 helps minimize these differences, some minor differences may still exist, particularly with respect to some relatively rare lymphocytic cancers that can be coded to either leukemia or lymphoma.

Starting with ICD-O-3, several myelodysplastic diseases and syndromes are considered malignant, and, therefore, are now reportable for cases diagnosed in 2001 and later and are included in these data. Leukemias that represent a disease progression from one of the myelodysplastic diseases or syndromes diagnosed in 2001 and forward are no longer reportable.

For pediatric cancers, differences in incidence rates may be due to changes between the second and third edition of the International Classification of Childhood Cancers

(ICCC). Two changes in the ICCC-3 classification are main contributors to this change.

1) Burkitt lymphoma and unspecified lymphoma, which were separated from non-Hodgkin lymphoma previously are combined with non-Hodgkin lymphoma; 2) Some lymphomas, which were grouped in the miscellaneous lymphoreticular neoplasms previously, are now included in the non-Hodgkin lymphoma category. Pilocytic astrocytoma is considered to have uncertain behavior in the published version of ICD-O-3, but is reportable as a malignant cancer in North America. Including the childhood astrocytomas in the category of malignant brain tumors may introduce differences between childhood brain cancer rates in North America compared to other areas of the world that may not include these tumors as malignant.

In addition, mesothelioma and Kaposi sarcoma cases are reported as separate categories. This change has little or no impact on most rates for specific cancers.

Variable List

Demographic	State/Province
Demographic	Recode: Country
Demographic	Sex
Demographic	Recode: Age
Demographic	Recode: Race
Demographic	Recode: Hispanic
Cancer ID	Recode: Central Seq #
Cancer ID	Dx date year only
Cancer ID	Recode: Behavior
Cancer ID	Recode: Primary Site plus with Meso & KS
Cancer ID	Recode: ICCC
Cancer ID	Recode: CBTRUS for brain
Cancer ID	Recode: Histology
Cancer ID	Recode: Summary Stage
Cancer ID	Laterality
Cancer ID	Grade
Cancer ID	Diagnostic confirmation
Cancer ID	Recode: Report Source <i>CBTRUS brain and CSN histologic groupings—Under development</i>
<i>Derived</i>	
Derived	MP using IARC rules & SEER
Derived	County-Level Urban/Rural Status Code
Derived	County-Level Poverty Code
<i>Derived</i>	<i>SES Composite (SEER)—under development</i>

Variable Codes:

State: Name of state/province (Will include only high quality registries following CiNA monograph standards)

Country: 2 codes (US, Canada)—Derived code

Sex: T (includes all categories), M, F, unk

Age: 5-year aggregates; 0-4, 5-9,...75-79, 80-84, 85+, **no unknown age**

Race: (US only)

National: W, B, API, AIAN (AIAN is based on CHDSA counties only; recoded into race variable), Unk; and W, B, O, unk. Race suppressed following CiNA monograph standards (<6 in numerator).

Race/ethnicity:

Hispanic All Races, Non-Hispanic White, Non-Hispanic Black, Non-Hispanic Other, Non-Hispanic Unknown Race, Unknown Hispanic (based on NHIA). Race/ethnicity suppressed following CiNA monograph standards (<6 in numerator).

Central Seq #: variable collapsed

One primary only, 1st of 2 or more primaries; 2nd of 2 or more primaries; 3rd of 3 or more primaries, 4th of 4 or more primaries; 5th of 5 or more primaries; 6th or more of 6 or more primaries

Year of Diagnosis: 1995-2013

Behavior:

Benign, Borderline, In situ, Malignant, Only Malignant in ICD-O-3, No longer Reportable in ICD-O-3, Only malignant 2010+

Primary Site (03): based on ICD-O-3 regardless of diagnosis date; suppression rules apply

All Sites

Oral Cavity and Pharynx

Lip

Tongue

Salivary Gland

Floor of Mouth

Gum and Other Mouth

Nasopharynx

Tonsil

Oropharynx

Hypopharynx

Other Oral Cavity and Pharynx

Digestive System

Esophagus

Stomach

Small Intestine

Colon and Rectum

Colon excluding Rectum

Cecum

Appendix

Ascending Colon

Hepatic Flexure

Transverse Colon

Splenic Flexure

Descending Colon

Sigmoid Colon

Large Intestine, NOS

Rectum and Rectosigmoid Junction

Rectosigmoid Junction

Rectum

Anus, Anal Canal and Anorectum

Liver and Intrahepatic Bile Duct

Liver

Intrahepatic Bile Duct

Gallbladder

Other Biliary

Pancreas

Retroperitoneum

Peritoneum, Omentum and Mesentery

Other Digestive Organs

- Respiratory System
 - Nose, Nasal Cavity and Middle Ear
 - Larynx
 - Lung and Bronchus
 - Pleura
 - Trachea, Mediastinum and Other
- Respiratory Organs
- Bones and Joints
- Soft Tissue including Heart
- Skin excluding Basal and Squamous
 - Melanoma of the Skin
 - Other Non-Epithelial Skin
- Breast
- Female Genital System
 - Cervix Uteri
 - Corpus and Uterus, NOS
 - Corpus Uteri
 - Uterus, NOS
 - Ovary
 - Vagina
 - Vulva
 - Other Female Genital Organs
- Male Genital System
 - Prostate
 - Testis
 - Penis
 - Other Male Genital Organs
- Urinary System
 - Urinary Bladder
 - Kidney and Renal Pelvis
 - Ureter
 - Other Urinary Organs
- Eye and Orbit
- Brain and Other Nervous System
 - Brain
 - Cranial Nerves Other Nervous System
- Endocrine System
 - Thyroid
 - Other Endocrine including Thymus
- Lymphoma
 - Hodgkin Lymphoma
 - Hodgkin - Nodal
 - Hodgkin - Extranodal

- Non-Hodgkin Lymphoma
 - NHL - Nodal
 - NHL - Extranodal
- Myeloma
- Leukemia
 - Lymphocytic Leukemia
 - Acute Lymphocytic Leukemia
 - Chronic Lymphocytic Leukemia
 - Other Lymphocytic Leukemia
 - Myeloid and Monocytic Leukemia
 - Acute Myeloid Leukemia
 - Acute Monocytic Leukemia
 - Chronic Myeloid Leukemia
 - Other Myeloid/Monocytic Leukemia
 - Other Leukemia
 - Other Acute Leukemia
 - Aleukemic, Subleukemic and NOS
- Mesothelioma
- Kaposi Sarcoma
- Miscellaneous

Histology (o3): based on ICD-O-3 regardless of diagnosis date

8000/0: Neoplasm, benign
8000/1: Neoplasm, uncertain whether benign or malignant
8000/2: Neoplasm, in situ
8000/3: Neoplasm, malignant
8001/0: Tumor cells, benign
8001/1: Tumor cells, uncertain whether benign or malignant
8001/3: Tumor cells, malignant
8002/3: Malignant tumor, small cell type
8003/1
8003/3: Malignant tumor, giant cell type
8004/0
8004/3: Malignant tumor, spindle cell type
8005/1
8005/3: Malignant tumor, clear cell type
8010/0: Epithelial tumor, benign
8010/1
8010/2: Carcinoma in situ, NOS
8010/3: Carcinoma, NOS
8011/2: Epithelioma, in situ
8011/3: Epithelioma, malignant
8012/2: Large cell carcinoma in situ
8012/3: Large cell carcinoma, NOS
8013/3: Large cell neuroendocrine carcinoma
8014/2
8014/3: Large cell carcinoma with rhabdoid phenotype
8015/3: Glassy cell carcinoma
8020/2
8020/3: Carcinoma, undifferentiated type, NOS
8021/3: Carcinoma, anaplastic type, NOS
8022/2: Pleomorphic carcinoma in situ
8022/3: Pleomorphic carcinoma
8030/2: Giant cell and spindle cell carcinoma in situ
8030/3: Giant cell and spindle cell carcinoma
8031/2: Giant cell carcinoma in situ
8031/3: Giant cell carcinoma
8032/2: Spindle cell carcinoma in situ
8032/3: Spindle cell carcinoma
8033/2: Pseudosarcomatous carcinoma, in situ
8033/3: Pseudosarcomatous carcinoma

8034/3: Polygonal cell carcinoma
 8035/3: Carcinoma with osteoclast-like giant cells
 8040/1: Tumorlet, NOS
 8040/3: Tumorlet, malignant
 8041/2: Small cell carcinoma in situ
 8041/3: Small cell carcinoma, NOS
 8042/2: Oat cell carcinoma in situ
 8042/3: Oat cell carcinoma
 8043/3: Small cell carcinoma, fusiform cell
 8044/3: Small cell carcinoma, intermediate cell
 8045/3: Combined small cell carcinoma
 8046/2: Non-small cell carcinoma in situ
 8046/3: Non-small cell carcinoma
 8050/0
 8050/2: Papillary carcinoma in situ
 8050/3: Papillary carcinoma, NOS
 8051/2: Verrucous papilloma in situ
 8051/3: Verrucous carcinoma, NOS
 8052/2: Papillary squamous cell carcinoma, non-invasive
 8052/3: Papillary squamous cell carcinoma
 8053/2
 8053/3: Papillary squamous cell carcinoma, inverted
 8060/3
 8070/2: Squamous cell carcinoma in situ, NOS
 8070/3: Squamous cell carcinoma, NOS
 8071/2: Squamous cell carcinoma in situ, keratinizing, NOS
 8071/3: Squamous cell carcinoma, keratinizing, NOS
 8072/2: Squamous cell CIS, large cell, nonkeratinizing
 8072/3: Squamous cell ca., large cell, nonkeratinizing
 8073/2: Squamous cell CIS, small cell, nonkeratinizing
 8073/3: Squamous cell ca., small cell, nonkeratinizing
 8074/2: Squamous cell carcinoma in situ, spindle cell
 8074/3: Squamous cell carcinoma, spindle cell
 8075/2: Squamous cell carcinoma in situ, adenoid
 8075/3: Squamous cell carcinoma, adenoid
 8076/2: Squamous cell CIS with questionable stromal invasion
 8076/3: Squamous cell carcinoma, micro-invasive
 8077/2: Squamous intraepithelial neoplasia, grade III
 8077/3: Squamous cell ca. & Grade III
 8078/3: Squamous cell carcinoma with horn formation
 8080/2: Queyrat erythroplasia

8080/3: Queyrat erythroplasia, malignant
 8081/2: Bowen disease
 8081/3: Bowen disease, malignant
 8082/3: Lymphoepithelial carcinoma
 8083/2: Basaloid squamous cell carcinoma in situ
 8083/3: Basaloid squamous cell carcinoma
 8084/3: Squamous cell carcinoma, clear cell type
 8090/2: Basal cell carcinoma in situ
 8090/3: Basal cell carcinoma, NOS
 8091/2: Multicentric basal cell carcinoma in situ
 8091/3: Multifocal superficial basal cell carcinoma
 8092/3: Infiltrating basal cell carcinoma, NOS
 8093/3: Basal cell carcinoma, fibroepithelial
 8094/2: Basosquamous carcinoma in situ
 8094/3: Basosquamous carcinoma
 8095/3: Metatypical carcinoma
 8097/2
 8097/3: Basal cell carcinoma, nodular
 8098/3: Adenoid basal cell carcinoma
 8100/3: Trichoepithelioma, malignant
 8101/3
 8102/3: Trichilemmocarcinoma
 8103/0
 8103/3: Pilar tumor, malignant
 8110/3: Pilomatrix carcinoma
 8120/0
 8120/2: Transitional cell carcinoma in situ
 8120/3: Transitional cell carcinoma, NOS
 8121/2: Transitional cell carcinoma in situ, inverted, NOS
 8121/3: Schneiderian carcinoma
 8122/2
 8122/3: Transitional cell carcinoma, spindle cell
 8123/2: Basaloid carcinoma in situ
 8123/3: Basaloid carcinoma
 8124/2: Cloacogenic carcinoma in situ
 8124/3: Cloacogenic carcinoma
 8130/2: Papillary transitional cell carcinoma, non-invasive
 8130/3: Papillary transitional cell carcinoma
 8131/2: Transitional cell carcinoma in situ, micropapillary
 8131/3: Transitional cell carcinoma, micropapillary
 8140/0: Adenoma, NOS

8140/1: Atypical adenoma
 8140/2: Adenocarcinoma in situ
 8140/3: Adenocarcinoma, NOS
 8141/3: Scirrhus adenocarcinoma
 8142/2
 8142/3: Linitis plastica
 8143/2: Superficial spreading adenocarcinoma in situ
 8143/3: Superficial spreading adenocarcinoma
 8144/2: Adenocarcinoma in situ, intestinal type
 8144/3: Adenocarcinoma, intestinal type
 8145/2: Carcinoma in situ, diffuse type
 8145/3: Carcinoma, diffuse type
 8146/0: Monomorphic adenoma
 8146/3: Monomorphic adenocarcinoma
 8147/2
 8147/3: Basal cell adenocarcinoma
 8148/2: Glandular intraepithelial neoplasia, grade III
 8148/3: Glandular neoplasia, malignant, Grade III
 8149/3
 8150/3: Islet cell carcinoma
 8151/3: Insulinoma, malignant
 8152/3: Glucagonoma, malignant
 8153/3: Gastrinoma, malignant
 8154/3: Mixed islet cell and exocrine adenocarcinoma
 8155/3: Vipoma
 8156/3: Somatostatinoma, malignant
 8160/2: Bile duct adenocarcinoma in situ
 8160/3: Cholangiocarcinoma
 8161/3: Bile duct cystadenocarcinoma
 8162/2
 8162/3: Klatskin tumor
 8170/2: Hepatocellular carcinoma in situ
 8170/3: Hepatocellular carcinoma, NOS
 8171/3: Hepatocellular carcinoma, fibrolamellar
 8172/0
 8172/3: Hepatocellular carcinoma, scirrhus
 8173/3: Hepatocellular carcinoma, spindle cell variant
 8174/3: Hepatocellular carcinoma, clear cell type
 8175/3: Hepatocellular carcinoma, pleomorphic type
 8180/2
 8180/3: Combined hepatocellular ca. & cholangiocarcinoma

8190/3: Trabecular adenocarcinoma
8200/2: Adenoid cystic carcinoma in situ
8200/3: Adenoid cystic carcinoma
8201/2: Cribriform carcinoma in situ
8201/3: Cribriform carcinoma
8202/0: Microcystic adenoma
8202/3
8210/2: Adenocarcinoma in situ in adenomatous polyp
8210/3: Adenocarcinoma in adenomatous polyp
8211/2: Tubular adenocarcinoma in situ
8211/3: Tubular adenocarcinoma
8212/2
8212/3
8213/2: Serrated adenocarcinoma, in situ
8213/3: Serrated adenocarcinoma
8214/3: Parietal cell carcinoma
8215/3: Adenocarcinoma of anal glands
8220/2: Adenocarcinoma in situ in adenomatous polyposis coli
8220/3: Adenocarcinoma in adenomatous polyposis coli
8221/2: Adenoca. in situ in mult. adenomatous polyposis coli
8221/3: Adenocarcinoma in mult. adenomatous polyposis coli
8230/2: Duct carcinoma in situ, solid type
8230/3: Solid carcinoma, NOS
8231/3: Carcinoma simplex
8240/2: Carcinoid tumor, in situ
8240/3: Carcinoid tumor, malignant
8241/2
8241/3: Enterochromaffin cell carcinoid
8242/0
8242/3: Enterochromaffin-like cell tumor, malignant
8243/2
8243/3: Goblet cell carcinoid
8244/3: Composite carcinoid
8245/2
8245/3: Adenocarcinoid tumor
8246/2: Neuroendocrine carcinoma in situ
8246/3: Neuroendocrine carcinoma
8247/2: Merkel cell carcinoma in situ
8247/3: Merkel cell carcinoma
8248/3: Apudoma
8249/3: Atypical carcinoid tumor

8250/2: Bronchiolo-alveolar adenocarcinoma in situ
 8250/3: Bronchiolo-alveolar adenocarcinoma
 8251/3: Alveolar adenocarcinoma
 8252/2: Bronchiolo-alveolar carcinoma, non-mucinous, in situ
 8252/3: Bronchiolo-alveolar carcinoma, non-mucinous
 8253/2: Bronchiolo-alveolar carcinoma, mucinous, in situ
 8253/3: Bronchiolo-alveolar carcinoma, mucinous
 8254/3: Bronchiolo-alveolar ca., mucinous & non-mucinous
 8255/2: Adenocarcinoma in situ with mixed subtypes
 8255/3: Adenocarcinoma with mixed subtypes
 8260/0: Papillary adenoma, NOS
 8260/1
 8260/2: Papillary adenocarcinoma in situ, NOS
 8260/3: Papillary adenocarcinoma, NOS
 8261/2: Adenocarcinoma in situ in villous adenoma
 8261/3: Adenocarcinoma in villous adenoma
 8262/2: Villous adenocarcinoma in situ
 8262/3: Villous adenocarcinoma
 8263/2: Adenocarcinoma in situ in tubulovillous adenoma
 8263/3: Adenocarcinoma in tubulovillous adenoma
 8264/3
 8270/0: Chromophobe adenoma
 8270/1: Chromophobe adenoma, borderline
 8270/2
 8270/3: Chromophobe carcinoma
 8271/0: Prolactinoma
 8271/1
 8271/3: Prolactinoma, malignant
 8272/0: Pituitary adenoma, NOS
 8272/1: Pituitary, borderline malignancy
 8272/3: Pituitary carcinoma, NOS
 8280/0: Acidophil adenoma
 8280/3: Acidophil carcinoma
 8281/0: Mixed acidophil-basophil adenoma
 8290/0: Oxyphilic adenoma
 8290/2: Oxyphilic adenocarcinoma in situ
 8290/3: Oxyphilic adenocarcinoma
 8300/0: Basophil adenoma
 8300/3: Basophil carcinoma
 8310/0
 8310/2: Clear cell adenocarcinoma in situ

8310/3: Clear cell adenocarcinoma, NOS
8312/2: Renal cell carcinoma in situ, NOS
8312/3: Renal cell carcinoma
8313/3: Clear cell adenocarcinofibroma
8314/3: Lipid-rich carcinoma
8315/2
8315/3: Glycogen-rich carcinoma
8316/2: Cyst-associated renal cell carcinoma in situ
8316/3: Cyst-associated renal cell carcinoma
8317/3: Renal cell carcinoma, chromophobe type
8318/3: Renal cell carcinoma, sarcomatoid
8319/2
8319/3: Collecting duct carcinoma
8320/2
8320/3: Granular cell carcinoma
8321/3
8322/3: Water-clear cell adenocarcinoma
8323/0: Mixed cell adenoma
8323/2: Mixed cell adenocarcinoma in situ
8323/3: Mixed cell adenocarcinoma
8325/3: Metanephric adenomacarcinoma
8330/2: Follicular adenocarcinoma in situ
8330/3: Follicular adenocarcinoma, NOS
8331/3: Follicular adenocarcinoma well differentiated
8332/3: Follicular adenocarcinoma trabecular
8333/3: Fetal adenocarcinoma
8334/0
8335/2: Macrofollicular carcinoma in situ
8335/3: Follicular carcinoma, minimally invasive
8336/3
8337/3: Insular carcinoma
8340/2: Papillary carcinoma in situ, follicular variant
8340/3: Papillary carcinoma, follicular variant
8341/0
8341/2: Papillary microcarcinoma in situ
8341/3: Papillary microcarcinoma
8342/3: Papillary carcinoma, oxyphilic cell
8343/2: Papillary carcinoma, encapsulated, in situ
8343/3: Papillary carcinoma, encapsulated
8344/2
8344/3: Papillary carcinoma, columnar cell

8345/3: Medullary carcinoma with amyloid stroma
8346/3: Mixed medullary-follicular carcinoma
8347/3: Mixed medullary-papillary carcinoma
8350/3: Nonencapsulated sclerosing carcinoma
8360/1: Multiple endocrine adenomas
8360/3
8361/3
8370/0
8370/2: Adrenal cortical carcinoma in situ
8370/3: Adrenal cortical carcinoma
8372/0
8380/2: Endometrioid adenocarcinoma in situ
8380/3: Endometrioid carcinoma
8381/2
8381/3: Endometrioid adenofibroma, malignant
8382/2: Endometrioid adenoca in situ, secretory variant
8382/3: Endometrioid adenocarcinoma, secretory variant
8383/3: Endometrioid adenocarcinoma, ciliated cell variant
8384/2: Adenocarcinoma, endocervical type, in situ
8384/3: Adenocarcinoma, endocervical type
8390/2: Skin appendage carcinoma in situ
8390/3: Skin appendage carcinoma
8392/3: Syringofibroadenocarcinoma
8400/2: Sweat gland adenocarcinoma in situ
8400/3: Sweat gland adenocarcinoma
8401/2: Apocrine adenocarcinoma in situ
8401/3: Apocrine adenocarcinoma
8402/2: Nodular hidradenoma, in situ
8402/3: Nodular hidradenoma, malignant
8403/3: Malignant eccrine spiradenoma
8405/3: Papillary hidradenocarcinoma
8406/3: Papillary syringadenocarcinoma
8407/2
8407/3: Sclerosing sweat duct carcinoma
8408/3: Eccrine papillary adenocarcinoma
8409/2: Eccrine poroma, in situ
8409/3: Eccrine poroma, malignant
8410/2: Sebaceous adenocarcinoma in situ
8410/3: Sebaceous adenocarcinoma
8413/2: Eccrine adenocarcinoma, in situ
8413/3: Eccrine adenocarcinoma

8420/2
 8420/3: Ceruminous adenocarcinoma
 8430/2: Mucoepidermoid carcinoma in situ
 8430/3: Mucoepidermoid carcinoma
 8440/0
 8440/2: Cystadenocarcinoma in situ
 8440/3: Cystadenocarcinoma, NOS
 8441/0
 8441/2: Serous cystadenocarcinoma in situ, NOS
 8441/3: Serous cystadenocarcinoma, NOS
 8442/1: Serous cystadenoma, borderline malignancy
 8442/2: Serous cystadenocarcinoma in situ
 8442/3: Proliferating serous carcinoma
 8443/3: Clear cell cystadenocarcinoma
 8444/3: Clear cell cystic tumor, malignant
 8450/2: Papillary cystadenocarcinoma in situ, NOS
 8450/3: Papillary cystadenocarcinoma, NOS
 8451/1: Papillary cystadenoma, borderline malignancy
 8451/3
 8452/0
 8452/1
 8452/2
 8452/3: Solid pseudopapillary carcinoma
 8453/2: Intraductal papillary-mucinous ca., non-invasive
 8453/3: Intraductal papillary-mucinous carcinoma, invasive
 8460/2: Papillary serous cystadenocarcinoma in situ, NOS
 8460/3: Papillary serous cystadenocarcinoma
 8461/2: Serous surface papillary carcinoma, in situ
 8461/3: Serous surface papillary carcinoma
 8462/1: Serous papillary cystic tumor, borderline malignancy
 8462/2: Serous papillary cystadenocarcinoma in situ
 8462/3: Papillary serous cystadenocarcinoma
 8463/3: Serous surface papillary carcinoma
 8470/2: Mucinous cystadenocarcinoma, non-invasive
 8470/3: Mucinous cystadenocarcinoma, NOS
 8471/2: Papillary mucinous cystadenocarcinoma in situ, NOS
 8471/3: Papillary mucinous cystadenocarcinoma
 8472/1: Mucinous cystic tumor of borderline malignancy
 8472/2: Mucinous cystic adenocarcinoma in situ
 8472/3: Mucinous cystadenocarcinoma
 8473/1: Papillary mucinous cystadenoma, borderline malignancy.

8473/2: Papillary mucinous cystadenocarcinoma, in situ
 8473/3: Papillary pseudomucinous cystadenocarcinoma
 8480/2: Mucinous adenocarcinoma in situ
 8480/3: Mucinous adenocarcinoma
 8481/2: Mucin-producing adenocarcinoma in situ
 8481/3: Mucin-producing adenocarcinoma
 8482/3: Mucinous adenocarcinoma, endocervical type
 8490/0: Signet ring cell tumor, benign
 8490/2: Signet ring cell carcinoma in situ
 8490/3: Signet ring cell carcinoma
 8500/2: Intraductal carcinoma, noninfiltrating, NOS
 8500/3: Infiltrating duct carcinoma, NOS
 8501/2: Comedocarcinoma, non-infiltrating
 8501/3: Comedocarcinoma, NOS
 8502/2: Secretory carcinoma in situ of breast
 8502/3: Secretory carcinoma of breast
 8503/2: Noninfiltrating intraductal papillary adenocarcinoma
 8503/3: Intraductal papillary adenocarcinoma with invasion
 8504/2: Noninfiltrating intracystic carcinoma
 8504/3: Intracystic carcinoma, NOS
 8507/2: Intraductal micropapillary carcinoma
 8507/3: Ductal carcinoma, micropapillary
 8508/2: Cystic hypersecretory carcinoma in situ
 8508/3: Cystic hypersecretory carcinoma
 8510/2: Medullary carcinoma in situ, NOS
 8510/3: Medullary carcinoma, NOS
 8512/2: Medullary carcinoma in situ with lymphoid stroma
 8512/3: Medullary carcinoma with lymphoid stroma
 8513/2
 8513/3: Atypical medullary carcinoma
 8514/2
 8514/3: Duct carcinoma, desmoplastic type
 8520/2: Lobular carcinoma in situ
 8520/3: Lobular carcinoma, NOS
 8521/2: Ductular carcinoma in situ
 8521/3: Infiltrating ductular carcinoma
 8522/2: Intraductal and lobular in situ carcinoma
 8522/3: Infiltrating duct and lobular carcinoma
 8523/2: Intraductal with other types of carcinoma in situ
 8523/3: Infiltrating duct mixed with other types of ca.
 8524/2: Lobular CIS with other CIS

8524/3: Infiltrating lobular mixed with other types of ca.
 8525/2
 8525/3: Polymorphous low grade adenocarcinoma
 8530/3: Inflammatory carcinoma
 8540/2: Paget disease, mammary, in situ
 8540/3: Paget disease, mammary
 8541/2: Paget disease in situ and intraductal carcinoma
 8541/3: Paget disease and infiltrating duct carcinoma
 8542/2: Paget disease in situ, extra mammary (except bone)
 8542/3: Paget disease, extramammary
 8543/2: Paget disease in situ and intraductal carcinoma
 8543/3: Paget disease and intraductal carcinoma
 8550/2: Acinar cell carcinoma in situ
 8550/3: Acinar cell carcinoma
 8551/3: Acinar cell cystadenocarcinoma
 8560/2: Squamous cell CIS and glandular papilloma
 8560/3: Adenosquamous carcinoma
 8561/0
 8561/3: Warthin tumor, malignant
 8562/2: Epithelial-myoepithelial carcinoma in situ
 8562/3: Epithelial-myoepithelial carcinoma
 8570/2: Adenocarcinoma in situ with squamous metaplasia
 8570/3: Adenocarcinoma with squamous metaplasia
 8571/3: Adenocarcinoma w. cartilaginous & osseous metaplasia
 8572/0: Adenoma with spindle cell metaplasia
 8572/3: Adenocarcinoma with spindle cell metaplasia
 8573/2: Adenocarcinoma in situ with apocrine metaplasia
 8573/3: Adenocarcinoma with apocrine metaplasia
 8574/2: Adenocarcinoma in situ with neuroendocrine differentiation
 8574/3: Adenocarcinoma with neuroendocrine differentiation
 8575/2
 8575/3: Metaplastic carcinoma, NOS
 8576/3: Hepatoid adenocarcinoma
 8580/2: Thymoma, in situ, NOS
 8580/3: Thymoma, malignant, NOS
 8581/2
 8581/3: Thymoma, type A, malignant
 8582/2
 8582/3: Thymoma, type AB, malignant
 8583/3: Thymoma, type B1, malignant
 8584/2

8584/3: Thymoma, type B2, malignant
 8585/3: Thymoma, type B3, malignant
 8586/3: Thymic carcinoma, NOS
 8588/3: Spindle epithelial tumor with thymus-like element
 8589/3: Carcinoma showing thymus-like element
 8590/3: Sex cord-gonadal stromal tumor, malignant, NOS
 8591/3
 8592/3
 8593/3: Malignant Stromal tumor, with sex cord elements
 8600/3: Thecoma, malignant
 8602/3: Sclerosing stromal tumor, malignant
 8620/2
 8620/3: Granulosa cell tumor, malignant
 8621/3: Granulosa cell-theca cell tumor, malignant
 8622/3: Juvenile granulosa cell tumor, malignant
 8623/3: Sex cord tumor with annular tubules, malignant
 8630/3: Androblastoma, malignant
 8631/3: Sertoli-Leydig cell tumor, poorly differentiated
 8632/3: Gynandroblastoma, malignant
 8633/3
 8634/3: Sertoli-Leydig, poor diff. w. heterologous elements
 8640/2
 8640/3: Sertoli cell carcinoma
 8642/3
 8650/2
 8650/3: Leydig cell tumor, malignant
 8670/2
 8670/3: Steroid cell tumor, malignant
 8680/0: Paraganglioma, benign
 8680/1: Paraganglioma, NOS
 8680/3: Paraganglioma, malignant
 8682/1
 8683/0
 8683/1
 8683/3: Gangliocytic paraganglioma, malignant
 8690/0
 8690/1: Glomus jugulare tumor, NOS
 8690/3: Glomus jugulare tumor, malignant
 8692/3: Carotid body tumor, malignant
 8693/1: Extra-adrenal paraganglioma, NOS
 8693/3: Extra-adrenal paraganglioma, malignant

8700/0
8700/3: Pheochromocytoma
8710/2
8710/3: Glomangiosarcoma
8711/0: Glomus tumor, NOS
8711/3: Glomus tumor, malignant
8712/0
8713/0
8713/3
8720/0: Pigmented nevus, NOS
8720/2: Melanoma in situ
8720/3: Malignant melanoma, NOS
8721/2: Nodular melanoma, in situ
8721/3: Nodular melanoma
8722/2: Balloon cell melanoma, in situ
8722/3: Balloon cell melanoma
8723/2: Melanoma in situ, regressing
8723/3: Malignant melanoma, regressing
8726/0: Magnocellular nevus
8726/1
8726/3: Malignant melanoma in magnocellular nevus
8727/3: Dysplastic nevus, malignant
8728/0
8728/1: Meningeal melanocytoma
8728/2
8728/3: Meningeal melanomatosis
8730/2: Amelanotic melanoma, in situ
8730/3: Amelanotic melanoma
8740/2: Melanoma in situ in junctional nevus
8740/3: Malignant melanoma in junctional nevus
8741/2: Precancerous melanosis, NOS
8741/3: Malignant melanoma in precancerous melanosis
8742/2: Lentigo maligna
8742/3: Lentigo maligna melanoma
8743/2: Superficial spreading melanoma, in situ
8743/3: Superficial spreading melanoma
8744/2: Acral lentiginous melanoma, in situ
8744/3: Acral lentiginous melanoma, malignant
8745/2: Desmoplastic melanoma, in situ
8745/3: Desmoplastic melanoma, malignant
8746/2: Mucosal lentiginous melanoma in situ

8746/3: Mucosal lentiginous melanoma
 8750/2
 8750/3
 8760/2: Melanoma in situ in compound nevus
 8760/3: Malignant melanoma in compound nevus
 8761/2: Melanoma in situ in giant pigmented nevus
 8761/3: Malignant melanoma in giant pigmented nevus
 8770/2: Epithelioid and spindle cell melanoma in situ
 8770/3: Mixed epithelioid and spindle cell melanoma
 8771/2: Epithelioid cell melanoma in situ
 8771/3: Epithelioid cell melanoma
 8772/0
 8772/2: Spindle cell melanoma in situ, NOS
 8772/3: Spindle cell melanoma, NOS
 8773/3: Spindle cell melanoma, type A
 8774/2
 8774/3: Spindle cell melanoma, type B
 8780/2
 8780/3: Blue nevus, malignant
 8790/3: Cellular blue nevus, malignant
 8800/0: Soft tissue tumor, benign
 8800/3: Sarcoma, NOS
 8801/3: Spindle cell sarcoma
 8802/3: Giant cell sarcoma
 8803/3: Small cell sarcoma
 8804/3: Epithelioid sarcoma
 8805/3: Undifferentiated sarcoma
 8806/3: Desmoplastic small round cell tumor
 8810/0: Fibroma, NOS
 8810/3: Fibrosarcoma, NOS
 8811/1
 8811/3: Fibromyxosarcoma
 8812/3: Periosteal fibrosarcoma
 8813/3: Fascial fibrosarcoma
 8814/3: Infantile fibrosarcoma
 8815/0: Solitary fibrous tumor
 8815/1
 8815/3: Solitary fibrous tumor, malignant
 8820/0: Elastofibroma
 8821/1: Aggressive fibromatosis
 8821/3: Aggressive fibromatosis, malignant

8822/2
8822/3: Abdominal fibromatosis, malignant
8823/3: Desmoplastic fibrosarcoma
8824/0
8824/1
8824/3: Myofibroma, malignant
8825/0: Myofibroblastoma
8825/1: Myofibroblastic tumor, NOS
8825/2
8825/3: Myofibroblastoma, malignant
8826/3: Angiomyofibroblastoma, malignant
8830/0: Fibrous histiocyoma, benign
8830/1
8830/3: Fibrous histiocyoma, malignant
8831/0
8831/3: Histiocyoma, NOS, malignant
8832/3: Dermatofibrosarcoma, NOS
8833/3: Pigmented dermatofibrosarcoma protuberans
8835/1
8835/3: Malignant plexiform fibrohistiocytic tumor
8836/1
8836/3: Malignant angiomatoid fibrous histiocyoma
8840/0
8840/3: Myxosarcoma
8841/1
8841/3: Angiomyxoma, malignant
8842/0
8842/3: Ossifying fibromyxoid tumor, malignant
8850/0: Lipoma, NOS
8850/1: Atypical lipoma
8850/3: Liposarcoma, NOS
8851/0: Fibrolipoma
8851/3: Liposarcoma, well differentiated
8852/3: Myxoid liposarcoma
8853/3: Round cell liposarcoma
8854/0
8854/3: Pleomorphic liposarcoma
8855/3: Mixed type liposarcoma
8856/0: Intramuscular lipoma
8856/3
8857/0

8857/3: Fibroblastic liposarcoma
8858/3: Dedifferentiated liposarcoma
8860/3: Angiomyoliposarcoma
8861/0: Angiolipoma, NOS
8861/3
8870/0
8870/3
8880/3
8881/1
8890/0: Leiomyoma, NOS
8890/3: Leiomyosarcoma, NOS
8891/3: Epithelioid leiomyosarcoma
8892/3
8893/3: Bizarre leiomyosarcoma
8894/0: Angiomyoma
8894/3: Angiomyosarcoma
8895/3: Myosarcoma
8896/3: Myxoid leiomyosarcoma
8897/1: Smooth muscle tumor, NOS
8897/3: Malignant tumor of smooth muscle
8900/0: Rhabdomyoma, NOS
8900/3: Rhabdomyosarcoma, NOS
8901/3: Pleomorphic rhabdomyosarcoma, adult type
8902/3: Mixed type rhabdomyosarcoma
8904/0
8910/3: Embryonal rhabdomyosarcoma
8912/3: Spindle cell rhabdomyosarcoma
8920/3: Alveolar rhabdomyosarcoma
8921/3: Rhabdomyosarcoma with ganglionic differentiation
8930/3: Endometrial stromal sarcoma
8931/3: Endometrial stromal sarcoma, low grade
8932/3
8933/2
8933/3: Adenosarcoma
8934/3: Carcinofibroma
8935/0: Stromal tumor, benign
8935/3: Stromal sarcoma, NOS
8936/2: Gastrointestinal stromal tumor, NOS, in situ
8936/3: Gastrointestinal stromal sarcoma
8940/0: Pleomorphic adenoma
8940/2

8940/3: Mixed tumor, malignant, NOS
 8941/2: Carcinoma in situ in pleomorphic adenoma
 8941/3: Carcinoma in pleomorphic adenoma
 8950/3: Mullerian mixed tumor
 8951/3: Mesodermal mixed tumor
 8959/3: Malignant cystic nephroma
 8960/1
 8960/3: Nephroblastoma, NOS
 8963/3: Malignant rhabdoid tumor
 8964/3: Clear cell sarcoma of kidney
 8970/3: Hepatoblastoma
 8971/3: Pancreatoblastoma
 8972/3: Pulmonary blastoma
 8973/3: Pleuropulmonary blastoma
 8974/3
 8980/3: Carcinosarcoma, NOS
 8981/3: Carcinosarcoma, embryonal type
 8982/0
 8982/2
 8982/3: Malignant myoepithelioma
 8983/2: Adenomyoepithelioma, in situ
 8983/3: Adenomyoepithelioma, malignant
 8990/0: Mesenchymoma, benign
 8990/1: Mesenchymoma, NOS
 8990/3: Mesenchymoma, malignant
 8991/3: Embryonal sarcoma
 9000/0: Brenner tumor, NOS
 9000/3: Brenner tumor, malignant
 9013/3: Adenofibroma, malignant
 9014/2: Serous adenocarcinofibroma, in situ
 9014/3: Serous adenocarcinofibroma
 9015/3: Mucinous adenocarcinofibroma
 9020/1: Phyllodes tumor, borderline
 9020/2
 9020/3: Phyllodes tumor, malignant
 9040/0
 9040/3: Synovial sarcoma, NOS
 9041/3: Synovial sarcoma, spindle cell
 9042/3: Synovial sarcoma, epithelioid cell
 9043/3: Synovial sarcoma, biphasic
 9044/3: Clear cell sarcoma, NOS (except of kidney M-8964/3)

9050/3: Mesothelioma, malignant
 9051/0
 9051/3: Fibrous mesothelioma, malignant
 9052/3: Epithelioid mesothelioma, malignant
 9053/3: Mesothelioma, biphasic, malignant
 9055/3: Multicystic mesothelioma, malignant
 9060/3: Dysgerminoma
 9061/2: Seminoma, in situ
 9061/3: Seminoma, NOS
 9062/3: Seminoma, anaplastic
 9063/2: Spermatocytic seminoma, in situ
 9063/3: Spermatocytic seminoma
 9064/0
 9064/1
 9064/2: Intratubular malignant germ cells
 9064/3: Germinoma
 9065/0
 9065/2
 9065/3: Germ cell tumor, nonseminomatous
 9070/2: Embryonal carcinoma, NOS, in situ
 9070/3: Embryonal carcinoma, NOS
 9071/2
 9071/3: Yolk sac tumor
 9072/3: Polyembryoma
 9073/3: Gonadoblastoma, malignant
 9080/0: Teratoma, benign
 9080/1: Teratoma, NOS
 9080/2: Teratoma, in situ
 9080/3: Teratoma, malignant, NOS
 9081/3: Teratocarcinoma
 9082/3: Malignant teratoma, undifferentiated
 9083/3: Malignant teratoma, intermediate
 9084/0: Dermoid cyst, NOS
 9084/1
 9084/3: Teratoma with malignant transformation
 9085/2: Mixed germ cell tumor, in situ
 9085/3: Mixed germ cell tumor
 9090/3: Struma ovarii, malignant
 9091/3: Strumal carcinoid, malignant
 9100/2: Choriocarcinoma in situ, NOS
 9100/3: Choriocarcinoma

9101/2: Choriocarcinoma combined w. other germ cell elements, in situ
 9101/3: Choriocarcinoma combined w. other germ cell elements
 9102/2
 9102/3: Malignant teratoma, trophoblastic
 9103/3: Partial hydatidiform mole, malignant
 9104/3: Malignant placental site trophoblastic tumor
 9105/3: Trophoblastic tumor, epithelioid
 9110/2
 9110/3: Mesonephroma, malignant
 9120/0: Hemangioma, NOS
 9120/1: Hemangioma, NOS, borderline
 9120/3: Hemangiosarcoma
 9121/0: Cavernous hemangioma
 9121/1: Cavernous hemangioma, borderline
 9121/3
 9122/0: Venous hemangioma
 9122/1
 9123/0: Racemose hemangioma
 9124/3: Kupffer cell sarcoma
 9125/0: Epithelioid hemangioma
 9125/3: Epithelioid hemangiosarcoma
 9130/0: Hemangioendothelioma, benign
 9130/1: Hemangioendothelioma, NOS
 9130/3: Hemangioendothelioma, malignant
 9131/0: Capillary hemangioma
 9131/3
 9133/1: Epithelioid hemangioendothelioma, NOS
 9133/3: Epithelioid hemangioendothelioma, malignant
 9135/1
 9136/1: Spindle cell hemangioendothelioma
 9136/3
 9140/3: Kaposi sarcoma
 9150/0: Hemangiopericytoma, benign
 9150/1: Hemangiopericytoma, NOS
 9150/3: Hemangiopericytoma, malignant
 9160/0: Angiofibroma, NOS
 9160/3: Angiofibrosarcoma
 9161/0: Acquired tufted hemangioma
 9161/1: Hemangioblastoma
 9161/3: Hemangioblastoma, malignant
 9170/0: Lymphangioma, NOS

9170/3: Lymphangiosarcoma
9171/3
9172/0
9173/0: Cystic lymphangioma
9173/3
9174/3
9175/3
9180/0: Osteoma, NOS
9180/3: Osteosarcoma, NOS
9181/3: Chondroblastic osteosarcoma
9182/3: Fibroblastic osteosarcoma
9183/3: Telangiectatic osteosarcoma
9184/3: Osteosarcoma in Paget disease
9185/3: Small cell osteosarcoma
9186/3: Central osteosarcoma
9187/3: Introsseous well differentiated osteosarcoma
9191/0
9192/3: Parosteal osteosarcoma
9193/3: Periosteal osteosarcoma
9194/3: High grade surface osteosarcoma
9195/3
9200/0
9200/1
9200/3: Malignant, osteosarcoma
9210/0
9210/1
9220/0: Chondroma, NOS
9220/1
9220/3: Chondrosarcoma, NOS
9221/3: Juxtacortical chondrosarcoma
9230/3: Chondroblastoma, malignant
9231/3: Myxoid chondrosarcoma
9240/3: Mesenchymal chondrosarcoma
9241/0
9241/3
9242/3: Clear cell chondrosarcoma
9243/3: Dedifferentiated chondrosarcoma
9250/1: Giant cell tumor of bone, NOS
9250/3: Giant cell tumor of bone, malignant
9251/1
9251/3: Malignant giant cell tumor of soft parts

9252/0: Tenosynovial giant cell tumor
 9252/3: Malignant tenosynovial giant cell tumor
 9260/3: Ewing sarcoma
 9261/3: Adamantinoma of long bones
 9262/0
 9270/3: Odontogenic tumor, malignant
 9282/3: Complex odontosarcoma
 9290/3: Ameloblastic odontosarcoma
 9300/0
 9302/3
 9310/3: Ameloblastoma, malignant
 9312/3: Squamous odontogenic tumor, malignant
 9321/3: Central odontogenic fibrosarcoma
 9330/3: Ameloblastic fibrosarcoma
 9340/3
 9341/3
 9342/3: Odontogenic carcinosarcoma
 9350/0: Craniopharyngioma, benign
 9350/1: Craniopharyngioma
 9350/3: Craniopharyngioma, malignant
 9351/0: Craniopharyngioma, adamantinomatous, benign
 9351/1: Adamantinomatous craniopharyngioma
 9351/3: Malignant craniopharyngioma, adamantinomatous
 9352/0: Papillary craniopharyngioma, benign
 9352/1: Papillary craniopharyngioma
 9360/0: Pinealoma, benign
 9360/1: Pinealoma, NOS
 9361/0: Pineocytoma, benign
 9361/1: Pineocytoma
 9361/3: Pineocytoma, malignant
 9362/0
 9362/1
 9362/3: Pineoblastoma
 9363/3: Melanotic neuroectodermal tumor, malignant
 9364/3: Peripheral neuroectodermal tumor
 9365/3: Askin tumor
 9370/0
 9370/1: Chordoma, borderline malignancy
 9370/3: Chordoma, NOS
 9371/3: Chondroid chordoma
 9372/3: Dedifferentiated chordoma

9373/3
 9380/0: Glioma, benign
 9380/1: Glioma, borderline
 9380/3: Glioma, malignant
 9381/0: Gliomatosis cerebri, benign
 9381/1
 9381/3: Gliomatosis cerebri
 9382/0: Mixed glioma, benign
 9382/3: Mixed glioma
 9383/0: Subependymoma, benign
 9383/1: Subependymoma
 9383/3: Subependymoma, malignant
 9384/0: Supependymal giant cell astrocytoma, benign
 9384/1: Supependymal giant cell astrocytoma
 9384/3: Subependymal giant cell astrocytoma, malignant
 9390/0: Choroid plexus papilloma, NOS
 9390/1: Atypical choroid plexus papilloma
 9390/3: Choroid plexus papilloma, malignant
 9391/0: Ependymoma, benign
 9391/1: Ependymoma, borderline
 9391/3: Ependymoma, NOS
 9392/3: Ependymoma, anaplastic
 9393/0: Papillary ependymoma, benign
 9393/1
 9393/3: Papillary ependymoma, NOS
 9394/0: Myxopapillary ependymoma, benign
 9394/1: Myxopapillary ependymoma
 9394/3: Myxopapillary ependymoma, malignant
 9400/0: Astrocytoma, benign
 9400/1: Astrocytoma, borderline malignancy
 9400/3: Astrocytoma, NOS
 9401/0: Astrocytoma, anaplastic, benign
 9401/3: Astrocytoma, anaplastic
 9410/3: Protoplasmic astrocytoma
 9411/0: Gemistocytic astrocytoma, benign
 9411/3: Gemistocytic astrocytoma
 9412/0: Desmoplastic infantile astrocytoma, benign
 9412/1: Desmoplastic infantile astrocytoma
 9412/3
 9413/0: Dysembryoplastic neuroepithelial tumor
 9413/1: Dysembryoplastic neuroepithelial tumor, borderline

9413/3: Dysembryoplastic neuroepithelial tumor, malignant
 9420/0
 9420/3: Fibrillary astrocytoma
 9421/3: Pilocytic astrocytoma, malignant
 9423/3: Polar spongioblastoma
 9424/0
 9424/3: Pleomorphic xanthoastrocytoma
 9430/0
 9430/3: Astroblastoma
 9440/0: Glioblastoma, benign
 9440/1: Glioblastoma, NOS, borderline
 9440/3: Glioblastoma, NOS
 9441/3: Giant cell glioblastoma
 9442/1: Gliofibroma
 9442/3: Gliosarcoma
 9444/0
 9444/1: Chordoid glioma
 9444/3
 9450/0: Oligodendroglioma, NOS, benign
 9450/1: Oligodendroglioma, NOS, borderline
 9450/3: Oligodendroglioma, NOS
 9451/0
 9451/1
 9451/3: Oligodendroglioma, anaplastic
 9460/0
 9460/3: Oligodendroblastoma
 9470/0
 9470/3: Medulloblastoma, NOS
 9471/3: Desmoplastic medulloblastoma
 9472/3: Medullomyoblastoma
 9473/0
 9473/3: Primitive neuroectodermal tumor
 9474/3: Large cell medulloblastoma
 9480/3: Cerebellar sarcoma, NOS
 9490/0: Ganglioneuroma
 9490/1: Ganglioneuroma, borderline
 9490/3: Ganglioneuroblastoma
 9492/0: Gangliocytoma
 9492/1
 9493/0: Dysplastic gangliocytoma of cerebellum
 9500/0: Neuroblastoma, NOS, benign

9500/2: Neuroblastoma, in situ, NOS
 9500/3: Neuroblastoma, NOS
 9501/3: Medulloepithelioma, NOS
 9502/3: Teratoid medulloepithelioma
 9503/0
 9503/3: Neuroepithelioma, NOS
 9504/3
 9505/0: Ganglioglioma, benign
 9505/1: Ganglioglioma, NOS
 9505/3: Ganglioglioma, anaplastic
 9506/0: Central neurocytoma, benign
 9506/1: Central neurocytoma
 9506/3: Neurocytoma, malignant
 9508/3: Atypical teratoid/rhabdoid tumor
 9510/3: Retinoblastoma, NOS
 9511/3: Retinoblastoma, differentiated
 9512/3: Retinoblastoma, undifferentiated
 9513/3: Retinoblastoma, diffuse
 9520/0
 9520/3: Olfactory neurogenic tumor
 9521/3: Olfactory neurcytoma
 9522/3: Olfactory neuroblastoma
 9523/3: Olfactory neuroepithelioma
 9530/0: Meningioma, NOS
 9530/1: Meningiomatosis, NOS
 9530/3: Meningioma, malignant
 9531/0: Meningothelial meningioma
 9531/1: Meningiothelial meningioma, borderline
 9531/3: Meningiothelial meningioma, malignant
 9532/0: Fibrous meningioma
 9532/1
 9532/3: Fibrous meningioma, malignant
 9533/0: Psammomatous meningioma
 9533/1
 9533/3: Psammomatous meningioma, malignant
 9534/0: Angiomatous meningioma
 9534/1
 9534/3: Angiomatous meningioma, malignant
 9535/0: Hemangioblastic meningioma
 9535/3: Hemangioblastic meningioma, malignant
 9537/0: Transitional meningioma

9537/1
 9537/3: Transitional meningioma, malignant
 9538/0: Clear cell meningioma, benign
 9538/1: Clear cell meningioma
 9538/3: Papillary meningioma
 9539/0: Atypical meningioma, benign
 9539/1: Atypical meningioma, NOS
 9539/3: Meningeal sarcomatosis
 9540/0: Neurofibroma, NOS
 9540/1: Neurofibromatosis, NOS
 9540/3: Malignant peripheral nerve sheath tumor
 9541/0: Melanotic neurofibroma
 9550/0: Plexiform neurofibroma
 9550/3: Plexiform neurofibrosarcoma
 9560/0: Neurilemoma, NOS
 9560/1: Neurinomatosis
 9560/3: Neurilemmoma, malignant
 9561/3: MPNST with rhabdomyoblastic differentiation
 9562/0: Neurothekeoma
 9562/3: Neurothekeoma, malignant
 9570/0: Neuroma, NOS
 9570/3
 9571/0: Perineurioma, NOS
 9571/1: Perineurioma, borderline malignancy
 9571/3: Perineurioma, malignant
 9580/0: Granular cell tumor, NOS
 9580/1
 9580/3: Granular cell tumor, malignant
 9581/3: Alveolar soft part sarcoma
 9582/0: Granular cell tumor of the sellar region
 9590/0
 9590/3: Malignant lymphoma, NOS
 9591/3: Malignant lymphoma, non-Hodgkin, NOS
 9596/3: B-cell lymphoma, between diffuse large B and HL (composite HL and NHL)
 9597/3: Primary cutaneous follicle centre lymphoma
 9650/3: Classical Hodgkin lymphoma
 9651/3: Lymphocyte-rich classical Hodgkin lymphoma
 9652/3: Mixed cellularity classical Hodgkin lymphoma
 9653/3: Lymphocyte-depleted classical Hodgkin lymphoma
 9654/3: Hodgkin lymphoma, LD, diffuse fibrosis (OBS 2010+) see 9651/3
 9655/3: Hodgkin lymphoma, lymphocytic depleted, reticular

9659/3: Nodular lymphocyte predominant Hodgkin lymphoma
 9661/3: Hodgkin granuloma (OBS 2010+) see 9651/3
 9662/3: Hodgkin sarcoma (OBS 2010+) see 9651/3
 9663/3: Nodular sclerosis classical Hodgkin lymphoma
 9664/3: Hodgkin lymphoma, nodular sclerosis, cellular phase (OBS) see 9663/3
 9665/3: Hodgkin lymphoma, nodular sclerosis, grade 1 (OBS 2010+) see 9663/3
 9667/3: Hodgkin lymphoma, nodular sclerosis, grade 2 (OBS 2010+) see 9663/3
 9670/3: Malignant lymphoma, small B lymphocytes, NOS (OBS 2010+) see 9823/3
 9671/3: Lymphoplasmacytic lymphoma (NHL)
 9673/3: Mantle cell lymphoma
 9675/3: Malig lymphoma, mixed small & large cell, diffuse (OBS 2010+) see 9690/3
 9678/3: Primary effusion lymphoma
 9679/3: Primary mediastinal (thymic) large B-cell lymphoma
 9680/3: Diffuse large B-cell (NHL) lymphoma (DLBCL)
 9684/3: Malig. lymphoma, large B, diffuse, immunoblastic (OBS 2010+) See 9680/3
 9687/3: Burkitt lymphoma
 9688/3: T-cell histiocyte-rich large B-cell lymphoma
 9689/3: Splenic marginal zone (B-cell) lymphoma
 9690/3: Follicular lymphoma, NOS
 9691/3: Follicular lymphoma, grade 2
 9695/3: Follicular lymphoma, grade 1
 9698/3: Follicular lymphoma, grade 3
 9699/3: Extranodal marginal zone lymphoma of mucosal-assoc. lymphoid tissue-MALT
 9700/3: Mycosis fungoides
 9701/3: Sezary syndrome
 9702/3: Peripheral (mature) T-cell lymphoma, NOS
 9705/3: Angioimmunoblastic T-cell lymphoma
 9708/3: Subcutaneous panniculitis-like T-cell lymphoma
 9709/3: Primary cutaneous T-cell lymphoma
 9712/3: Intravascular large B-cell lymphoma
 9714/3: Anaplastic large cell (T-cell and Null cell) lymphoma, ALK-positive
 9716/3: Hepatosplenic (gamma-delta) T-cell lymphoma
 9717/3: Enteropathy-associated T-cell (intestinal) lymphoma
 9718/3: Primary cutaneous CD30-pos. T-cell (lymphoma) lymphoproliferative disor.
 9719/3: Extranodal NK--/T-cell lymphoma, (nasal and) nasal type
 9724/3: Systemic EBV pos T-cell lymphoprolif dis of child
 9726/3: Primary cutaneous gamma-delta T-cell lymphoma
 9727/3: Blastic plasmacytoid dendritic cell neoplasm (prec b-cell leuk/lymph)
 9728/3: Precursor B-lymphoblastic lymphoma (OBS 2010+) See 9811/3
 9729/3: Precursor T--cell lymphoblastic lymphoma, NOS (OBS 2010+) See 9837/3
 9731/3: Solitary plasmacytoma of bone/plasmacytoma, NOS

9732/3: Plasma cell (multiple) myeloma
 9733/3: Plasma cell leukemia (OBS 2010+) See 9732/3
 9734/3: Extraosseous (extramedullary) plasmacytoma
 9735/3: Plasmablastic lymphoma
 9737/3: ALK positive large B-cell lymphoma
 9738/3: Large B-cell lymph HHV8 multicentric Castleman dis
 9740/3: Mast cell sarcoma
 9741/3: Malignant mastocytosis
 9742/3: Mast cell leukemia
 9750/1
 9750/3: Malignant histiocytosis (OBS 2010+) see 9751/3
 9751/0
 9751/1: Langerhans cell histiocytosis, NOS
 9751/3: Langerhans cell histiocytosis (malignant) (NOS)
 9752/0
 9752/1: Langerhans cell histiocytosis, unifocal (OBS 2010+) see 9751/3
 9752/3
 9753/1
 9753/3: Langerhans cell histiocytosis, multifocal, malig (OBS 2010+) see 9751/3
 9754/1: Langerhans cell histiocytosis, disseminated, borderline
 9754/3: Langerhans cell histiocytosis, disseminated (OBS 2010+) see 9751/3
 9755/3: Histiocytic sarcoma
 9756/3: Langerhans cell sarcoma
 9757/3: Interdigitating dendritic cell sarcoma
 9758/3: Follicular dendritic cell sarcoma
 9760/3: Immunoproliferative disease, NOS (OBS 2010+) see 9761/3 or 9762/3
 9761/3: Waldenstrom macroglobulinemia
 9762/3: Heavy chain disease
 9764/3: Immunoproliferative small intestinal disease (OBS 2010+) see code 9762
 9765/3: Monoclonal gammopathy, malignant
 9766/1: Angiocentric immunoproliferative lesion
 9766/3: Angiocentric immunoproliferative lesion, malignant
 9768/3
 9769/3: Immunoglobulin deposition disease (malignant)
 9800/3: Leukemia, NOS
 9801/3: Acute (undifferentiated) leukemia
 9805/3: Acute biphenotypic leukemia (OBS 2010+) see codes 9806-9809
 9806/3: Mixed pheno acute leuk w/t(9;22)(q34;q11.2);BCR-ABL1
 9807/3: Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged
 9808/3: Mixed phenotype acute leukemia, B/myeloid, NOS
 9809/3: Mixed phenotype acute leukemia, T/myeloid, NOS

9811/3: B lymphoblastic leuk/lymph, NOS
 9812/3: B lymphobl leuk/lymph w/t(9;22)(q34;q11.2); BCR-ABL1
 9813/3: B lymphobl leuk/lymph w/t(v;11q23); MLL rearranged
 9814/3: B lymphobl leuk/lymph w/t(12;21)(p13;q22);TEL-AML1
 9815/3: B lymphoblastic leuk/lymph w/hyperdiploidy
 9816/3: B lymphobl leuk/lymph w/hypodiploidy (hypodip ALL)
 9817/3: B lymphobl leuk/lymph w/t(5;14)(q31;q32); IL3-IGH
 9818/3: B lymphobl leuk/lymph w/t(1;19)(q23;p13.3); E2A PBX1
 9820/3: Lymphoid leukemia, NOS
 9823/3: Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-cell)
 9826/3: Burkitt cell leukemia
 9827/3: Adult T-cell leukemia/lymphoma (HTLV-1 pos.)
 9831/3: T-cell large granular lymphocytic leukemia
 9832/3: Prolymphocytic leukemia, NOS
 9833/3: B-cell prolymphocytic leukemia
 9834/3: T-cell prolymphocytic leukemia
 9835/3: Precursor cell lymphoblastic leukemia, NOS (OBS 2010+) see 9811/3
 9836/3: Precursor B-cell lymphoblastic leukemia (OBS 2010+) see code 9811/3
 9837/3: Adult T-cell leukemia/lymphoma
 9840/3: Acute erythroid leukemia (M6 type)
 9860/3: Myeloid leukemia, NOS
 9861/3: Acute myeloid leukemia
 9863/3: Chronic myeloid leukemia, NOS
 9865/3: Acute myeloid leukemia w/t(6;9)(p23;q34) DEK-NUP214
 9866/3: Acute promyelocytic leukemia (AML with t(15;17)(q22;q12)) PML/RARA
 9867/3: Acute myelomonocytic leukemia
 9869/3: Acute myeloid leuk. inv(3)(q21;q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
 9870/3: Acute basophilic leukemia
 9871/3: AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11
 9872/3: Acute myeloid leukemia with minimal differentiation
 9873/3: Acute myeloid leukemia without maturation
 9874/3: Acute myeloid leukemia with maturation
 9875/3: Chronic myelogenous leukemia, BCR/ABL positive
 9876/3: Atypical chronic myeloid leukemia, BCR/ABL negative
 9891/3: Acute monoblastic and monocytic leukemia
 9895/3: AML with myelodysplasia-related changes (multilineage dysplasia)
 9896/3: Acute myeloid leukemia, t(8;21)(q22;q22) RUNX1-RUNX1T1
 9897/3: Acute myeloid leukemia with t(9;11)(p22;q23);MLLT3-MLL
 9898/3: Myeloid leukemia associated w/Down Syndrome
 9910/3: Acute megakaryoblastic leukemia
 9911/3: Acute myeloid leuk (megakaryobl) w/t(1;22)(p13;q13)

9920/3: Therapy-related (acute) myeloid neoplasm
 9930/3: Myeloid sarcoma
 9931/3: Acute panmyelosis with myelofibrosis
 9940/3: Hairy cell leukemia
 9945/3: Chronic myelomonocytic leukemia, NOS
 9946/3: Juvenile myelomonocytic leukemia
 9948/3: Aggressive NK-cell leukemia
 9950/3: Polycythemia vera
 9960/3: Chronic myeloproliferative disease, NOS (OBS 2010+) see 9975/3
 9961/3: Primary myelofibrosis/myelosclerosis with myeloid metaplasia
 9962/3: Essential thrombocythemia
 9963/3: Chronic neutrophilic leukemia
 9964/3: Chronic eosinophilic leukemia (hypereosinophilic syndrome), NOS
 9965/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange
 9966/3: Myeloid and lymphoid neoplasms w/PDGFRB rearrange
 9967/3: Myeloid and lymphoid neoplasm w/FGFR1 abnormalities
 9970/1: Lymphoproliferative disorder, borderline
 9970/3: Lymphoproliferative disorder (disease), NOS (malig only prior to 2010)
 9971/3: Polymorphic PTLD
 9975/3: Myelodysp./myeloproliferative neoplasm unclass (malig only before 2010)
 9980/3: Refractory anemia
 9982/3: Refractory anemia with sideroblasts
 9983/3: Refractory anemia with excess blasts
 9984/3: Refractory anemia w. excess blasts in transformation
 9985/3: Refractory cytopenia with multilineage dysplasia
 9986/3: Myelodysplastic syndrome associated with isolated del(5q)
 9987/3: Therapy related myelodysplastic syndrome, NOS (OBS 2010+) See 9920/3
 9989/3: Myelodysplastic syndrome, unclassifiable or NOS
 9991/3: Refractory neutropenia
 9992/3: Refractory thrombocytopenia

Summary Stage: single variable based on SEER Summary Stage 77, 2000, Derived
(combined based on dx year)
IS, L, R, D, unknown

Laterality:

Not a paired site, Right (origin of primary), Left (origin of primary), Only one
side—side unspecified, Bilateral-single primary, Paired site—midline tumor,
Paired site—but no information

Grade:

Well differentiated; Grade I
Moderately differentiated; Grade II
Poorly differentiated; Grade III
Undifferentiated; anaplastic; Grade
IV
T-cell
B-cell; pre-B; B-precursor
Null cell; non T-non B
NK cell; natural killer cell
Unknown

ICCC: based on ICD-O-3 regardless of diagnosis date

I Leukemias, myeloproliferative &
myelodysplastic diseases

I(a) Lymphoid leukemias

I(b) Acute myeloid leukemias

I(c) Chronic myeloproliferative diseases

I(d) Myelodysplastic syndrome and other
myeloproliferative

I(e) Unspecified and other specified leukemias

II Lymphomas and reticuloendothelial neoplasms

II(a) Hodgkin lymphomas

II(b) Non-Hodgkin lymphomas (except Burkitt
lymphoma)

II(c) Burkitt lymphoma

II(d) Miscellaneous lymphoreticular neoplasms

II(e) Unspecified lymphomas

III CNS and misc intracranial and intraspinal
neoplasms

III(a) Ependymomas and choroid plexus tumor

III(b) Astrocytomas

III(c) Intracranial and intraspinal embryonal
tumors

III(d) Other gliomas

III(e) Other specified intracranial/intraspinal
neoplasms

III(f) Unspecified intracranial and intraspinal
neoplasms

IV Neuroblastoma and other peripheral nervous
cell tumors

IV(a) Neuroblastoma and ganglioneuroblastoma

IV(b) Other peripheral nervous cell tumors

V Retinoblastoma

VI Renal tumors

VI(a) Nephroblastoma and other nonepithelial
renal tumors

VI(b) Renal carcinomas

VI(c) Unspecified malignant renal tumors

VII Hepatic tumors

VII(a) Hepatoblastoma

VII(b) Hepatic carcinomas

VII(c) Unspecified malignant hepatic tumors

VIII Malignant bone tumors

VIII(a) Osteosarcomas

VIII(b) Chondrosarcomas

- VIII(c) Ewing tumor and related sarcomas of bone
- VIII(d) Other specified malignant bone tumors
- VIII(e) Unspecified malignant bone tumors
- IX Soft tissue and other extraosseous sarcomas
 - IX(a) Rhabdomyosarcomas
 - IX(b) Fibrosarcomas, peripheral nerve & other fibrous
 - IX(c) Kaposi sarcoma
 - IX(d) Other specified soft tissue sarcomas
 - IX(e) Unspecified soft tissue sarcomas
- X Germ cell & trophoblastic tumors & neoplasms of gonads
 - X(a) Intracranial & intraspinal germ cell tumors
 - X(b) Extracranial & extragonadal germ cell tumors
 - X(c) Malignant gonadal germ cell tumors
 - X(d) Gonadal carcinomas
 - X(e) Other and unspecified malignant gonadal tumors
- XI Other malignant epithelial neoplasms and melanomas
 - XI(a) Adrenocortical carcinomas
 - XI(b) Thyroid carcinomas
 - XI(c) Nasopharyngeal carcinomas
 - XI(d) Malignant melanomas
 - XI(e) Skin carcinomas
 - XI(f) Other and unspecified carcinomas
- XII Other and unspecified malignant neoplasms
 - XII(a) Other specified malignant tumors
 - XII(b) Other unspecified malignant tumors
- Not classified by ICCC or in situ

Report Source: only 2 codes—other; DCO or autopsy only

CBTRUS Brain groupings based on site and histology: Updated by CBTRUS, See Appendix A

MP based on IARC Rules: check Y/N

MP based on SEER Rules: check Y/N

County-Level Urban/Rural Status: Based on Beale codes
Metro, Non-Metro, unknown

County-level poverty: Based on ACS % living in poverty rolling 5 year-average (linked to date of diagnosis)
<5%, 5-9.9%, 10-19.99%, 20%+, unknown

SES Composite (SEER): based on ACS data, county-level not tract because we do not currently have denominator (US only). Components include: Occupation, Unemployment, Poverty, Income, Education, Housing (price, ownership, crowding).

Appendix A. CBTRUS site/histology groups for malignant and non-malignant brain and CNS tumors. The variable is histologic group for malignant (Table 2b) and non-malignant (Table 2c) brain and CNS tumors (based on Table 1).

Table 1. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Site Groupings

Site	ICD-O-3 ^a Site Code
Cerebrum	C71.0
Frontal lobe of brain	C71.1
Temporal lobe of brain	C71.2
Parietal lobe of brain	C71.3
Occipital lobe of brain	C71.4
Ventricle	C71.5
Cerebellum	C71.6
Brain stem	C71.7
Other brain	C71.8-C71.9
Overlapping lesion of brain	C71.8
Brain, NOS	C71.9
Spinal cord and cauda equina	C72.0-C72.1
Spinal cord	C72.0
Cauda equina	C72.1
Cranial nerves	C72.2-C72.5
Olfactory nerve	C72.2
Optic nerve	C72.3
Acoustic nerve	C72.4
Cranial nerve, NOS	C72.5
Other nervous system	C72.8-C72.9
Overlapping lesion of brain and central nervous system	C72.8
Nervous system, NOS	C72.9
Meninges (cerebral & spinal)	C70.0-C70.1, C70.9
Cerebral meninges	C70.0
Spinal meninges	C70.1
Meninges, NOS	C70.9
Pituitary and craniopharyngeal duct	C75.1-C75.2
Pituitary gland	C75.1
Craniopharyngeal duct	C75.2
Pineal gland	C75.3
Olfactory tumors of the nasal cavity ^b	C30.0

^aInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.

^bICD-O-3 histology codes 9522-9523 only.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.

Table 2b. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Malignant Histologies^a

Histology	ICD-O-3 ^b Histology Code ^c
Tumors of Neuroepithelial Tissue	
Piloicytic astrocytoma*	9421/1 [Included with malignant tumors], 9425/3 ^c
Diffuse astrocytoma*	9400/3, 9410/3, 9411/3, 9420/3
Anaplastic astrocytoma*	9401/3
Unique astrocytoma variants*	9381/3, 9424/3
Glioblastoma*	9440/3, 9441/3, 9442/3
Oligodendroglioma*	9450/3
Anaplastic oligodendroglioma*	9451/3, 9460/3
Oligoastrocytic tumors*	9382/3
Ependymal tumors*	9391/3, 9392/3, 9393/3
Glioma malignant, NOS*	9380/3, 9431/1, 9432/1 [Included with malignant tumors]
Choroid plexus tumors	9390/3
Other neuroepithelial tumors*	9423/3, 9430/3
Neuronal and mixed neuronal-glial tumors*	8680/3, 8693/3, 9505/3, 9522/3, 9523/3
Tumors of the pineal region	9362/3, 9395/3 ^c
Embryonal tumors	8963/3, 9364/3, 9470/3, 9471/3, 9472/3, 9473/3, 9474/3, 9480/3, 9490/3, 9500/3, 9501/3, 9502/3, 9508/3
Tumors of Cranial and Spinal Nerves	
Nerve sheath tumors	9540/3, 9560/3, 9561/3, 9571/3
Tumors of Meninges	
Meningioma	9530/3, 9538/3, 9539/3
Mesenchymal tumors	8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3, 8850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3, 8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3
Primary melanocytic lesions	8720/3, 8728/3, 8770/3, 8771/3
Other neoplasms related to the meninges	9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3
Lymphomas and Hemopoietic Neoplasms	
Lymphoma	9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3, 9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3, 9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3, 9705/3, 9714/3, 9719/3, 9728/3, 9729/3
Other hemopoietic neoplasms	9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3, 9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3
Germ Cell Tumors and Cysts	
Germ cell tumors, cysts and heterotopias	8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3, 9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3
Tumors of Sellar Region	
Tumors of the pituitary	8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3
Unclassified Tumors	
Hemangioma	9120/3, 9130/3, 9133/3, 9140/3
Neoplasm, unspecified	8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3
All other	8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3

^aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definitions.

^bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.

^cSee the CBTRUS website for additional information about the specific histology codes included in each group: <http://www.cbtrus.org>.

*All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.

Table 2c. Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Non-Malignant Histologies^a

Histology	ICD-O-3 ^b Histology Code ^c
Tumors of Neuroepithelial Tissue	
Unique astrocytoma variants ^a	9384/1
Ependymal tumors ^a	9383/1, 9394/1
Choroid plexus	9390/0,1
Other neuroepithelial tumors	9363/0, 9444/1
Neuronal and mixed neuronal-glial tumors ^a	8680/0,1, 8681/1, 8690/1, 8693/1, 9412/1, 9413/0, 9442/1, 9492/0 (excluding site C75.1), 9493/0, 9505/1, 9506/1, 9509/1
Tumors of the pineal region	9360/1, 9361/1
Embryonal tumors	9490/0
Tumors of Cranial and Spinal Nerves	
Nerve sheath tumors	9540/0,1, 9541/0, 9550/0, 9560/0,1, 9570/0, 9571/0
Other tumors of cranial and spinal nerves	9562/0
Tumors of Meninges	
Meningioma	9530/0,1, 9531/0, 9532/0, 9533/0, 9534/0, 9537/0, 9538/1, 9539/1
Mesenchymal tumors	8324/0, 8800/0, 8810/0, 8815/0, 8824/0,1, 8830/0,1, 8831/0, 8835/1, 8836/1, 8850/0,1, 8851/0, 8852/0, 8854/0, 8857/0, 8861/0, 8870/0, 8880/0, 8890/0,1, 8897/1, 8900/0, 8920/1, 8935/0,1, 8990/0,1, 9040/0, 9136/1, 9150/0,1, 9170/0, 9180/0, 9210/0, 9241/0, 9373/0
Primary melanocytic lesions	8728/0,1, 8770/0, 8771/0
Other neoplasms related to the meninges	9161/1, 9220/0,1, 9535/0
Lymphomas and Hemopoietic Neoplasms	
Other hemopoietic neoplasms	9740/1, 9751/1, 9752/1, 9753/1, 9766/1, 9970/1
Germ Cell Tumors and Cysts	
Germ cell tumors, cysts and heterotopias	8440/0, 9080/0,1, 9084/0
Tumors of Sellar Region	
Tumors of the pituitary	8040/0,1, 8140/0,1, 8146/0, 8260/0, 8270/0, 8271/0, 8272/0, 8280/0, 8281/0, 8290/0, 8300/0, 8310/0, 8323/0, 9492/0 (site C75.1 only), 9582/0
Craniopharyngioma	9350/1, 9351/1, 9352/1
Unclassified Tumors	
Hemangioma	9120/0, 9121/0, 9122/0, 9123/0, 9125/0, 9130/0,1, 9131/0, 9133/1
Neoplasm, unspecified	8000/0,1, 8001/0,1, 8005/0, 8010/0
All other	8452/1, 8711/0, 8713/0, 8811/0, 8840/0, 9173/0, 9580/0

^aIncludes all the histologies listed in the standard definition of reportable brain tumors from the Consensus Conference on Brain Tumor Definition.^bInternational Classification of Diseases for Oncology, 3rd Edition, 2000. World Health Organization, Geneva, Switzerland.^cSee the CBTRUS website for additional information about the specific histology codes included in each group: <http://www.cbtrus.org>.^{*}All or some of this histology is included in the CBTRUS definition of gliomas, including ICD-O-3 histology codes 9380-9384, 9391-9460.

Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; NOS, not otherwise specified.